Swallowing dysfunction treatment developer Phagenesis gobbled up $42 million in Series D financing, CEO Reinhard Krickl tells Axios exclusively.
Why it matters: Swallowing difficulties or dysphagia result from brain injuries like stroke and are linked with longer hospital stays and higher rates of complications and deaths.
